

1. Pardi E, Marcocci C, Borsari S, Saponaro F, Torregrossa L, Tancredi M, Raspini B, Basolo F, Cetani F. Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations Occur Rarely in Sporadic Parathyroid Adenomas. *J Clin Endocrinol Metab.* 2013 Jul;98(7):2800-10
2. Cetani F, Marcocci C. The use of positron emission tomography with(11)C-methionine in patients with primary hyperparathyroidism. *Endocrine.* 2013 Feb 3. [Epub ahead of print].
3. Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C, Del Prete M, Vescini F, Gianotti L, Cavalli L, Romagnoli E, Colao A, Cetani F, Marcocci C. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. *Clin Endocrinol (Oxf).* 2013 Jul;79(1):20-6.
4. Profilo MA, Sisti E, Marcocci C, Vitti P, Pinchera A, Nardi M, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Rago T, Marinò M. Thyroid volume and severity of graves' orbitopathy. *Thyroid.* 2013 Jan;23(1):97-102.
5. Rocchi R, Lenzi R, Marinò M, Latrofa F, Nardi M, Piaggi P, Mazzi B, Altea MA, Pinchera A, Vitti P, Marcocci C, Sellari-Franceschini S. Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction. *Thyroid.* 2012 Nov;22(11):1170-5.
6. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bornaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G; European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. *J Clin Endocrinol Metab.* 2012 Dec;97(12):4454-63.
7. Botta R, Lisi S, Marcocci C, Sellari-Franceschini S, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Sisti E, Casini G, Nardi M, Pinchera A, Vitti P, Marinò M. Enalapril reduces proliferation and hyaluronic Acid release in orbital fibroblasts. *Thyroid.* 2013 Jan;23(1):92-6.
8. Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyroidism. *Ther Adv Musculoskelet Dis.* 2012 Oct;4(5):357-68. PubMed
9. Belardi V, Fiore E, Giustarini E, Muller I, Sabatini S, Rosellini V, Seregini E, Agresti R, Marcocci C, Vitti P, Giani C. Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer? *J Endocrinol Invest.* 2012 Aug 29.
10. Cianferotti L, Marcocci C. Subclinical vitamin D deficiency. *Best Pract Res Clin Endocrinol Metab.* 2012 Aug;26(4):523-37. doi: 10.1016/j.beem.2011.12.007.
11. Zini M, Attanasio R, Cesareo R, Emmolo I, Frasoldati A, Gianotti L, Guglielmi R, Piovesan A, Procopio M, Scillitani A, Versari A, Bollerslev J, Rao DS, Marcocci C, Borretta G; Italian Association of Clinical Endocrinologists. AME

position statement: primary hyperparathyroidism in clinical practice. *J Endocrinol Invest.* 2012 Jul;35(7 Suppl):2-21.

12. Marcocci C, Marinò M. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. *Best Pract Res Clin Endocrinol Metab.* 2012 Jun;26(3):325-37.
13. Marcocci C, Altea MA, Leo M. Treatment options for Graves' orbitopathy. *Expert Opin Pharmacother.* 2012 Apr;13(6):795-806.
14. Cetani F, Pardi E, Borsari S, Marcocci C. Molecular pathogenesis of primary hyperparathyroidism. *J Endocrinol Invest.* 2011 Jul;34(7 Suppl):35-9.
15. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. *N Engl J Med.* 2011 Dec 22;365(25):2389-97.
16. Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, Viccica G, Pinchera A, Marcocci C. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. *J Endocrinol Invest.* 2012 Jul;35(7):655-60.
17. Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marinò M. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. *J Clin Endocrinol Metab.* 2012 Jan;97(1):E44-8.
18. Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J, Bartalena L; European Group of Graves' Orbitopathy. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. *Eur J Endocrinol.* 2012 Feb;166(2):247-53.
19. Marcocci C, Cetani F. Update on the use of cinacalcet in the management of primary hyperparathyroidism. *J Endocrinol Invest.* 2012 Jan;35(1):90-5.
20. Ambrosini CE, Cianferotti L, Picone A, Torregrossa L, Segnini G, Frustaci G, Cetani F, Basolo F, Marcocci C, Miccoli P. High-intensity focused ultrasound as an alternative to the surgical approach in primary hyperparathyroidism: a preliminary experience. *J Endocrinol Invest.* 2011 Oct;34(9):655-9.
21. Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. *Eur J Endocrinol.* 2011 Dec;165(6):851-64.
22. Donadio E, Giusti L, Cetani F, Da Valle Y, Ciregia F, Giannaccini G, Pardi E, Saponaro F, Torregrossa L, Basolo F, Marcocci C, Lucacchini A. Evaluation of formalin-fixed paraffin-embedded tissues in the proteomic analysis of parathyroid glands. *Proteome Sci.* 2011 Jun 8;9(1):29.
23. Adami S, Maugeri D, Toscano V, Topa G, Carminiti M, Brancati A, Massarotti M, Osella G, Malavolta N, Iolascon G, Cagnoni C, Camozzi V, Corradini C, Nardi A, Migliaccio S, Ulivieri FM, Resmini G, Valle D, Tauchmanová L, Silvestri S; ISSO Study Group, Italy. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO). *Clin Exp Rheumatol.* 2011 May-Jun;29(3):477-84.

24. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W; European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. *N Engl J Med*. 2011 May 19;364(20):1920-31.
25. Giusti L, Cetani F, Ciregia F, Da Valle Y, Donadio E, Giannaccini G, Banti C, Pardi E, Saponaro F, Basolo F, Berti P, Miccoli P, Pinchera A, Marcocci C, Lucacchini A. A proteomic approach to study parathyroid glands. *Mol Biosyst*. 2011 Mar;7(3):687-99.
26. Viccica G, Francucci CM, Marcocci C. The role of PPAR γ for the osteoblastic differentiation. *J Endocrinol Invest*. 2010;33(7 Suppl):9-12. Review.
27. Lisi S, Botta R, Lemmi M, Sellari-Franceschini S, Altea MA, Sisti E, Casini G, Nardi M, Marcocci C, Pinchera A, Marinò M. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. *J Endocrinol Invest*. 2011 Jul-Aug;34(7):521-7.
28. Bogazzi F, Rossi G, Lombardi M, Tomisti L, Sardella C, Manetti L, Curzio O, Marcocci C, Grasso L, Gasperi M, Martino E. Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects. *J Endocrinol Invest*. 2011 Sep;34(8):e200-3. doi: 10.3275/7228.
29. Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filippini P, Fiore E, Frediani Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G; Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro. [Guidelines for the diagnosis, prevention and treatment of osteoporosis]. *Reumatismo*. 2009 Oct-Dec;61(4):260-84.
30. Lazarus JH, Bartalena L, Marcocci C, Kahaly GJ, Krassas G, Wiersinga WM; UGOGO (European Group on Graves' Orbitopathy). Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. *J Endocrinol Invest*. 2010 Jun;33(6):409-13.
31. Viridis A, Cetani F, Giannarelli C, Banti C, Ghiadoni L, Ambrogini E, Carrara D, Pinchera A, Taddei S, Bernini G, Marcocci C. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. *J Clin Endocrinol Metab*. 2010 Feb;95(2):920-7.
32. Sellari-Franceschini S, Lenzi R, Santoro A, Muscatello L, Rocchi R, Altea MA, Nardi M, Megna L, Marcocci C. Lateral wall orbital decompression in Graves' orbitopathy. *Int J Oral Maxillofac Surg*. 2010 Jan;39(1):16-20.
33. Giannini S, Sella S, Silva Netto F, Cattelan C, Dalle Carbonare L, Lazzarin R, Marchini F, Rigotti P, Marcocci C, Cetani F, Pardi E, D'Angelo A, Realdi G, Bonfante L. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. *J Bone Miner Res*. 2010 Apr;25(4):841-8.

34. Cetani F, Pardi E, Banti C, Collecchi P, Viacava P, Borsari S, Fanelli G, Naccarato AG, Saponaro F, Berti P, Miccoli P, Pinchera A, Marcocci C. Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. *Endocr Relat Cancer*. 2010 Jan 29;17(1):1-6.
35. Leo M, Pinchera A, Marcocci C. Orbital lymphoma masquerading as thyroid-associated orbitopathy. *J Clin Endocrinol Metab*. 2009 Sep;94(9):3155-6.